M. Zhao - The First Affiliated Hospital, China Medical University

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 9 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II study

Q. Zhou, X. Meng,L. Sun, D. Huang, N. Yang,Y. Yu,M. Zhao, W. Zhuang,Y. Hu, Y. Pan, M. Sun, J. Shan,

ANNALS OF ONCOLOGY (2023): S1662-S1662

引用0浏览0引用

P2.08-01 TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)

C. Zhou, B.P. Levy, J. Sands, S. Parakh, S. Sugawara,K. Syrigos, J.S. Ahn,M. Zhao,C.-C. Lin,E. Felip,F. Cappuzzo,M. Reck,

Journal of Thoracic Oncologyno. 11 (2023): S327-S328

引用0浏览0引用

LBA69 Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): A randomized multicenter study

Y. Hu, F. Zhang,M. Zhao,Z. Zheng, H. Zhang, T. Jiang, Z. Liu, J. Wen, X. Gan, H. Wang, L. Wu, S. Cang,

Annals of Oncology (2023): S1312-S1312

引用0浏览0引用

A Phase II Trial Assessing the Safety and Efficacy of Tislelizumab Combined with Chemotherapy and Autologous NK Cells in Patients with ES-SCLC

L. Xu, X. Li, M. Xu, S. Li, T. Han, S. Shi, G. Liang, H. Li,M. Zhao

Journal of Thoracic Oncologyno. 11 (2023): S373-S373

引用0浏览0引用

TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)

C. Zhou, B. P. Levy, J. Sands, S. Parakh, S. Sugawara, K. Syrigos, J. S. Ahn,M. Zhao,C. -C. Lin, E. Felip, F. Cappuzzo, M. Reck,

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S327-S328

引用0浏览0引用

Consensus for HER2 alterations testing in non-small-cell lung cancer

S Ren, J Wang,J Ying,T Mitsudomi, D H Lee,Z Wang,Q Chu,P C Mack,Y Cheng, J Duan, Y Fan, B Han,

ESMO openno. 1 (2022): 100395-100395

引用30浏览0WOS引用

16P Camrelizumab monotherapy or plus apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A single-arm, open-label, multicenter, phase II study

M. Zhao, X. Liu, C. Yuan, W. Zheng, D. Zhang, Q. Long, J. Li, T. Han, L. Xu, H. Li,X. Li, S. Shi

Annals of Oncology（2022）

引用1浏览0引用

Tumor Response and Survival in Patients with Advanced Non-Small-Cell Lung Cancer: The Predictive Value of Chemotherapy-Induced Changes in Fibrinogen

X. Qu,J. Zhao,M. Zhao,B. Jin,P. Yu,X. Hu,Y. Teng,J. Zhang,Y. Luo,S. Zheng,Q. Zhou,Y. Liu

ANNALS OF ONCOLOGY（2012）

引用58浏览0引用

NP Chemotherapy Plus Endostar Compared with NP Alone as First-Line Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer: A Retrospective Study

M. Zhao,H. Deng,B. Jin,P. Yu,Y. Luo,X. Qu, Y. Teng, Q. Guan,Y. Liu

ANNALS OF ONCOLOGY（2012）

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn